Jardiance is part of the Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors class of diabetes drugs, which also includes Invokana and Farxiga.
The financial analysts who focus on the pharmaceutical sector were all abuzz earlier this week as regards an announcement about a new medical study concerning Jardiance.
From an August 20, 2015 Forbes article, “Sweet Victory: Eli Lilly’s Jardiance Is First Diabetes Drug To Reduce Heart Attacks And Strokes”, by reporter Matthew Herper, we get a sense of that excitement:
A big win for Eli Lilly this morning. Its diabetes drug Jardiance, co-marketed with Boehringer Ingelheim, is the first blood-sugar lowering pill ever to reduce the risk of heart attacks, strokes, and cardiovascular deaths in a big study, according to a press release issued this morning.
Of course, we need to wait to see full details from the study, not just the press release Lilly and Boehringer issued this morning….
However, despite this glory-moment for Eli Lilly and Boehringer, all is not well for Jardiance as well as the other SGLT-2 inhibitors such as Invokana and Farxiga.
This situation becomes apparent by the titles of these earlier articles:
Accordingly, we are anxious to see the September 2015 medical journal article which will have more details about this recent Jardiance study, and possibly some discussion about the side-effects risks associated with Jardiance.[Read this article in full at original source]
Invokana / Farxiga / Jardiance
Free Case Evaluation
Strictly Confidential, No Obligation.